greeksoup/ stock research
Stock research / United States / BNTX / Year to 31 December 2023

BioNTech SE (BNTX) annual results, year to 31 December 2023: revenue EUR 3,819 million, from the 20-F

BioNTech SE files a 20-F with the SEC once a year, in euros. In the year to 31 December 2023 it reported revenue of EUR 3,819 million ($4.1 billion at the year's average rate), down 77.9% on the year before. Its profit attributable to shareholders was EUR 930 million, down 90.1%, and diluted earnings per share EUR 3.83.

Revenue
EUR 3,819 million
-77.9% on the year
FY2017FY2023
Operating margin
18.1%
73.0% a year earlier
FY2017FY2023
Net income
EUR 930 million
-90.1% on the year
FY2017FY2023
Diluted EPS
EUR 3.83
-89.9% on the year
FY2017FY2023

this yearthe year beforeIn euros as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toDec 2022Dec 2023
Revenue17,3113,819
Cost of sales2,995600
Research and development1,5371,783
Operating profit12,643690
Finance costs18.923.9
Profit before tax12,9541,186
Income tax3,520256
Profit for the year9,434930
Profit attributable to shareholders9,434930
Filing20-F20-F
EUR million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toDec 2022Dec 2023
Diluted EPS37.773.83
Basic EPS38.783.87
Filing20-F20-F

EUR per ordinary share, as filed.

Cash flow

Year toDec 2022Dec 2023
Cash from operations13,5775,371
Purchase of property, plant and equipment329249
Free cash flow13,2485,122
Cash from investing-35.3-6,954
Cash from financing-1,419-779
Depreciation and amortisation123183
Dividends paid4840.0
Filing20-F20-F

EUR million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toDec 2022Dec 2023
Funded by
Equity attributable to shareholders20,05620,246
Borrowings, as filed212219
Lease liabilities210217
Other liabilities2,8012,325
Total equity and liabilities23,27923,006
Owned
Property, plant and equipment609757
Goodwill61.2362
Cash and cash equivalents13,87511,664
Trade and other receivables7,1462,156
Inventories440358
Other assets1,1487,710
Total assets23,27923,006
Filing20-F20-F

EUR million, at each fiscal year end.

Ratios on the filed lines

Year toDec 2022Dec 2023
Operating margin73.0%18.1%
Net margin54.5%24.4%
Free cash flow margin76.5%134.1%
Return on year-end equity47.0%4.6%
Effective tax rate27.2%21.6%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 December 2023, filed 30 July 2026: the filing. The figures are in euros as filed.